Rein Therapeutics Inc.(RNTX)Earnings, Financials & Key Ratios
RNTX•NASDAQ
$1.17
$20987 mkt cap·Price updated May 7, 2026
AboutRein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.Show more
- Revenue$0
- EBITDA-$65M-402505.7%
- Net Income-$63M-399614.0%
- EPS (Diluted)-3.51-2.6%
- ROE-205.24%-166351.8%
- ROIC-313.55%-39509.8%
RNTX Key Insights
Rein Therapeutics Inc. (RNTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Trading at only 0.0x book value
✗Weaknesses
- ✗Weak Piotroski F-Score: 1/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
RNTX Price & Volume
Rein Therapeutics Inc. (RNTX) stock price & volume — 10-year historical chart
Loading chart...
RNTX Growth Metrics
Rein Therapeutics Inc. (RNTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-903.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-80426.6%
Return on Capital
10 Years-15.85%
5 Years-15.85%
3 Years-26.33%
Last Year-78.87%
RNTX Peer Comparison
Rein Therapeutics Inc. (RNTX) competitors in Clinical-Stage Biopharma Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATXI | 1.75M | 0.55 | -0.61 | -266.67% | -160.63% | |||
 NKTR | 1.69B | 83.37 | -8.57 | -43.89% | -297.07% | -399.1% | 1.66 | |
 INVA | 1.93B | 22.80 | 6.91 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PULM | 4.75M | 1.30 | -0.92 | -100% | -135.49% | |||
 INSM | 22.62B | 104.80 | -16.35 | 66.73% | -210.54% | -168.36% | 1.04 | |
 GILD | 166.4B | 134.06 | 19.77 | 2.4% | 30.99% | 42.33% | 1.09 | |
 UTHR | 24.95B | 569.18 | 20.43 | 10.61% | 40.61% | 19.24% | ||
 MNKD | 1.1B | 3.55 | 177.50 | 22.23% | -6.63% |
Compare RNTX vs Peers
Rein Therapeutics Inc. (RNTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNTX Income Statement
Rein Therapeutics Inc. (RNTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 20.5K | 26.61K | 27.65K | 16.28K | 65.11M | 23.77M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 9.33K | 9.6K | 9.68K | 11.36K | 13.86M | 11.42M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 11.17K | 17.01K | 17.97K | 3.99K | 14.25M | 12.35M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 928 | 37M | 0 |
| Operating Income | -20.5K▲ 0% | -26.61K▼ 29.8% | -27.65K▼ 3.9% | -16.28K▲ 41.1% | -65.11M▼ 399949.2% | -23.77M▲ 0% |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -29.81% | -3.92% | 41.13% | -399949.15% | - |
| EBITDA | -20.33K | -26.48K | -27.48K | -16.16K | -65.05M | -60.59M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | - | -30.25% | -3.75% | 41.2% | -402505.68% | -932.04% |
| D&A (Non-Cash Add-back) | 163 | 121 | 169 | 119 | 63K | 1K |
| EBIT | -20.5K | -26.61K | -27.65K | -15.35K | -28.11M | -60.59M |
| Net Interest Income | 0 | 0 | 0 | 600 | 400K | 700 |
| Interest Income | 0 | 0 | 0 | 600 | 400K | 700 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -661 | 441 | 318 | 544 | 800K | -36.66M |
| Pretax Income | -21.16K▲ 0% | -26.16K▼ 23.7% | -27.33K▼ 4.5% | -15.73K▲ 42.4% | -64.31M▼ 408697.4% | -60.43M▲ 0% |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | -1.54M | -1.54M |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 2.4% | 2.56% |
| Net Income | -21.16K▲ 0% | -26.16K▼ 23.7% | -27.33K▼ 4.5% | -15.73K▲ 42.4% | -62.88M▼ 399614.0% | -58.88M▲ 0% |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | - | -23.67% | -4.45% | 42.43% | -399613.96% | -903.08% |
| Net Income (Continuing) | -21.16K | -26.16K | -27.33K | -15.73K | -62.77M | -58.88M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.00▲ 0% | -5.89▼ 490733.3% | -6.02▼ 2.2% | -3.42▲ 43.2% | -3.51▼ 2.6% | -2.23▲ 0% |
| EPS Growth % | - | - | -2.21% | 43.19% | -2.63% | -80426.6% |
| EPS (Basic) | -0.00 | -5.89 | -6.02 | -3.42 | -3.51 | - |
| Diluted Shares Outstanding | 17.43M | 4.44K | 4.54K | 4.6K | 17.94K | 26.36M |
| Basic Shares Outstanding | 17.43M | 4.44K | 4.54K | 4.6K | 17.94K | 26.36M |
| Dividend Payout Ratio | - | - | - | - | - | - |
RNTX Balance Sheet
Rein Therapeutics Inc. (RNTX) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Total Current Assets | 16.33M | 48.18M | 21.87M | 18.27M | 13.66M | 5.17M |
| Cash & Short-Term Investments | 13.8M | 45.93M | 21.24M | 17.31M | 12.87M | 4.05M |
| Cash Only | 7.05M | 3.6M | 5.19M | 17.31M | 12.87M | 4.05M |
| Short-Term Investments | 6.76M | 42.33M | 16.05M | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - |
| Other Current Assets | 593K | 25K | 631K | 746K | 676K | 997K |
| Total Non-Current Assets | 15K | 304K | 134K | 87.74M | 55.58M | 48.53M |
| Property, Plant & Equipment | 15K | 280K | 110K | 19K | 1K | 0 |
| Fixed Asset Turnover | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 6.33M | 0 | 6.33M |
| Intangible Assets | 0 | 0 | 0 | 79.2M | 48.53M | 42.2M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 24K | 24K | 2.19M | 2K | 3.12M |
| Total Assets | 16.34M▲ 0% | 48.48M▲ 196.7% | 22.01M▼ 54.6% | 106.01M▲ 381.7% | 69.24M▼ 34.7% | 53.71M▲ 0% |
| Asset Turnover | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 196.68% | -54.61% | 381.7% | -34.68% | -172.51% |
| Total Current Liabilities | 3.96M | 4.51M | 3.38M | 4.38M | 5.75M | 5.74M |
| Accounts Payable | 1.6M | 1.21M | 1.72M | 1.19M | 911K | 4.12M |
| Days Payables Outstanding | - | - | - | - | - | - |
| Short-Term Debt | 168K | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 243K | 60K | 181K | 206K | 3.36M | 911K |
| Current Ratio | 4.12x | 10.69x | 6.46x | 4.17x | 2.38x | 2.38x |
| Quick Ratio | 4.12x | 10.69x | 6.46x | 4.17x | 2.38x | 2.38x |
| Cash Conversion Cycle | - | - | - | - | - | - |
| Total Non-Current Liabilities | 219K | 69K | 0 | 94.74M | 9.1M | 1.77M |
| Long-Term Debt | 219K | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 69K | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 3.33M | 8.82M | 14.14M |
| Other Non-Current Liabilities | 0 | 0 | 0 | 91.41M | 277K | 90.29M |
| Total Liabilities | 4.18M | 4.58M | 3.38M | 99.12M | 14.85M | 7.52M |
| Total Debt | 387K | 162K | 33K | 48K | 0 | 0 |
| Net Debt | -6.66M | -3.44M | -5.16M | -17.27M | -12.87M | -4.05M |
| Debt / Equity | 0.03x | 0.00x | 0.00x | 0.01x | - | 0.00x |
| Debt / EBITDA | - | - | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | - | - | 0.07x |
| Interest Coverage | - | - | - | - | - | - |
| Total Equity | 12.16M▲ 0% | 43.9M▲ 261.0% | 18.62M▼ 57.6% | 6.89M▼ 63.0% | 54.39M▲ 689.8% | 46.19M▲ 0% |
| Equity Growth % | - | 260.99% | -57.58% | -63.02% | 689.78% | 498% |
| Book Value per Share | 0.70 | 9887.54 | 4102.60 | 1497.59 | 3032.22 | 1.75 |
| Total Shareholders' Equity | 12.16M | 43.9M | 18.62M | 6.89M | 54.39M | 46.19M |
| Common Stock | 44K | 91K | 91K | 91K | 108K | 111K |
| Retained Earnings | -219.29M | -245.46M | -272.79M | -288.52M | -351.4M | -369.3M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -2K | -13K | -48K | -63K | -18K | -44K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
RNTX Cash Flow Statement
Rein Therapeutics Inc. (RNTX) cash flow — operating, investing & free cash flow history
| Line item | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|
| Cash from Operations | -20.48M | -23.75M | -24.86M | -19.81M | -22.29M | -22.29M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | - | -16.01% | -4.68% | 20.34% | -12.54% | 67.13% |
| Net Income | -21.16M | -26.16M | -27.33M | -15.73M | -62.88M | -58.88M |
| Depreciation & Amortization | 163K | 121K | 169K | 119K | 63K | 1K |
| Stock-Based Compensation | 1.89M | 2.26M | 2.08M | 1.19M | 1.12M | 653K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -95K | -213K | -208K | -4K | 37M | 38.85M |
| Working Capital Changes | -1.28M | 242K | 420K | -5.38M | 2.41M | -1.57M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 116K | -386K | 510K | -4.98M | -279K | 3.04M |
| Cash from Investing | 6.41M | -35.92M | 26.46M | 16.2M | 0 | 0 |
| Capital Expenditures | -5K | -157K | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | -96K | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 208K | 66K | 0 | 42K | 0 | 0 |
| Cash from Financing | 15.8M | 55.66M | 0 | 15.79M | 17.82M | 7.35M |
| Debt Issued (Net) | 387K | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1000K | 1000K | 0 | 0 | 1000K | 368K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 74K | 0 | 15.79M | 7.17M | 6.98M |
| Net Change in Cash | 1.74M▲ 0% | -4.01M▼ 331.4% | 1.59M▲ 139.7% | 12.12M▲ 660.3% | -4.47M▼ 136.9% | -13.63M▲ 0% |
| Free Cash Flow | -20.48M▲ 0% | -23.91M▼ 16.7% | -24.86M▼ 4.0% | -19.81M▲ 20.3% | -22.29M▼ 12.5% | -20.95M▲ 0% |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | - | -16.75% | -3.99% | 20.34% | -12.54% | -19.88% |
| FCF per Share | -1.17 | -5384.95 | -5477.70 | -4307.29 | -1242.67 | -1242.67 |
| FCF Conversion (FCF/Net Income) | 967.81x | 907.89x | 909.84x | 1259.09x | 0.35x | 0.36x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |
RNTX Key Ratios
Rein Therapeutics Inc. (RNTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|
| Return on Equity (ROE) | -0.09% | -0.09% | -0.12% | -205.24% | -127.48% |
| Return on Invested Capital (ROIC) | -0.09% | -0.08% | -0.79% | -313.55% | -313.55% |
| Debt / Equity | 0.00x | 0.00x | 0.01x | - | 0.00x |
| FCF Conversion | 907.89x | 909.84x | 1259.09x | 0.35x | 0.36x |
RNTX Frequently Asked Questions
Rein Therapeutics Inc. (RNTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Rein Therapeutics Inc. (RNTX) grew revenue by 0.0% over the past year. Growth has been modest.
Rein Therapeutics Inc. (RNTX) reported a net loss of $58.9M for fiscal year 2024.
Dividend & Returns
Rein Therapeutics Inc. (RNTX) has a return on equity (ROE) of -205.2%. Negative ROE indicates the company is unprofitable.
Rein Therapeutics Inc. (RNTX) had negative free cash flow of $21.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More RNTX
Rein Therapeutics Inc. (RNTX) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates